Optimization of antibiotics for cystic fibrosis pulmonary exacerbations due to highly resistant nonlactose fermenting Gram negative bacilli: Meropenemâvaborbactam and cefiderocol
Sign Up to like & getrecommendations! Published in 2021 at "Pediatric Pulmonology"
DOI: 10.1002/ppul.25552
Abstract: We are writing this letter to provide an update of published information on antibiotics for cystic fibrosis (CF) pulmonary exacerbations to the State of the Art articles by Zobell et al. Information on meropenemâvaborbactam and… read more here.
Keywords: cystic fibrosis; meropenem vaborbactam; pulmonary exacerbations; vaborbactam cefiderocol ... See more keywords